Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza

Vaccine

Volumn 26, Issue 19, 2008, Pages 2335-2343

  Rosas, Cristina ^a   Van de Walle, Gerlinde R ^a   Metzger, Stephan M ^a   Hoelzer, Karin ^a   Dubovi, Edward J ^a   Kim, Sung G ^a   Parrish, Colin R ^a   Osterrieder, Nikolaus ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

Canine influenza; EHV 1; H3

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DOG; DOG DISEASE; EQUINE HERPES VIRUS; EXPERIMENTAL INFECTION; FEMALE; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A H3N8; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; STRUCTURAL HOMOLOGY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TRANSMISSION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; BODY TEMPERATURE; DOG DISEASES; DOGS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HERPESVIRUS 1, EQUID; INFLUENZA A VIRUS, H3N8 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SEVERITY OF ILLNESS INDEX; VACCINES, SYNTHETIC; VIRAL LOAD; VIRUS SHEDDING;

EID: 42649115096     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.02.064     Document Type: Article

References (30)

1. Neumann G., and Kawaoka Y. Host range restriction and pathogenicity in the context of influenza pandemic. Emerg Infect Dis 12 6 (2006) 881-886
2. Crawford P.C., Dubovi E.J., Castleman W.L., Stephenson I., Gibbs E.P., Chen L., et al. Transmission of equine influenza virus to dogs. Science 310 5747 (2005) 482-485
3. Paillot R., Hannant D., Kydd J.H., and Daly J.M. Vaccination against equine influenza: quid novi?. Vaccine 24 19 (2006) 4047-4061
4. van Maanen C., van Essen G.J., Minke J., Daly J.M., and Yates P.J. Diagnostic methods applied to analysis of an outbreak of equine influenza in a riding school in which vaccine failure occurred. Vet Microbiol 93 4 (2003) 291-306
5. Animal Health Diagnostic Center. Emerging Issues, D. L. W. s. 2007. (GENERIC) Ref Type: Internet Communication.
6. Patel J.R., and Heldens J. Equine herpesviruses 1 (EHV-1) and 4 (EHV-4)-epidemiology, disease and immunoprophylaxis: a brief review. Vet J 170 1 (2005) 14-23
7. van Maanen C. Equine herpesvirus 1 and 4 infections: an update. Vet Q 24 2 (2002) 58-78
8. Hubert P.H., Birkenmaier S., Rziha H.J., and Osterrieder N. Alterations in the equine herpesvirus type-1 (EHV-1) strain RacH during attenuation. Zentralbl Veterinarmed B 43 1 (1996) 1-14
9. Neubauer A., Meindl A., and Osterrieder N. Mutations in the US2 and glycoprotein B genes of the equine herpesvirus 1 vaccine strain RacH have no effects on its attenuation. Berl Munch Tierarztl Wochenschr 112 9 (1999) 351-354
10. Osterrieder N., Hubert P.H., Brandmuller C., and Kaaden O.R. A touchdown PCR for the differentiation of equine herpesvirus type 1 (EHV-1) field strains from the modified live vaccine strain RacH. J Virol Methods 50 1-3 (1994) 129-136
11. Rosas C.T., Goodman L.B., von Einem J., and Osterrieder N. Equine herpesvirus type 1 modified live virus vaccines: quo vaditis?. Expert Rev Vaccines 5 1 (2006) 119-131
12. Rosas C.T., Konig P., Beer M., Dubovi E.J., Tischer B.K., and Osterrieder N. Evaluation of the vaccine potential of an equine herpesvirus type 1 vector expressing bovine viral diarrhea virus structural proteins. J Gen Virol 88 Pt 3 (2007) 748-757
13. Rosas C.T., Tischer B.K., Perkins G.A., Wagner B., Goodman L.B., and Osterrieder N. Live-attenuated recombinant equine herpesvirus type 1 (EHV-1) induces a neutralizing antibody response against West Nile virus (WNV). Virus Res 125 1 (2007) 69-78
14. Trapp S., von Einem J., Hofmann H., Kostler J., Wild J., Wagner R., et al. Potential of equine herpesvirus 1 as a vector for immunization. J Virol 79 9 (2005) 5445-5454
15. Rudolph J., and Osterrieder N. Equine herpesvirus type 1 devoid of gM and gp2 is severely impaired in virus egress but not direct cell-to-cell spread. Virology 293 2 (2002) 356-367
16. Tischer B.K., von Einem J., Kaufer B., and Osterrieder N. Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40 2 (2006) 191-197
17. Karaca K., Dubovi E.J., Siger L., Robles A., Audonnet J.C., Jiansheng Y., et al. Evaluation of the ability of canarypox-vectored equine influenza virus vaccines to induce humoral immune responses against canine influenza viruses in dogs. Am J Vet Res 68 2 (2007) 208-212
18. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37 4 (1999) 937-943
19. Spackman E., Senne D.A., Myers T.J., Bulaga L.L., Garber L.P., Perdue M.L., et al. Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes. J Clin Microbiol 40 9 (2002) 3256-3260
20. Bublot M., Pritchard N., Swayne D.E., Selleck P., Karaca K., Suarez D.L., et al. Development and use of fowlpox vectored vaccines for avian influenza. Ann NY Acad Sci 1081 (2006) 193-201
21. Minke J.M., Toulemonde C.E., Dinic S., Cozette V., Cullinane A., and Audonnet J.C. Effective priming of foals born to immune dams against influenza by a canarypox-vectored recombinant influenza H3N8 vaccine. J Comp Pathol 137 Suppl 1 (2007) S76-S80
22. Minke J.M., Toulemonde C.E., Coupier H., Guigal P.M., Dinic S., Sindle T., et al. Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge. Am J Vet Res 68 2 (2007) 213-219
23. Brave A., Ljungberg K., Wahren B., and Liu M.A. Vaccine delivery methods using viral vectors. Mol Pharm 4 1 (2007) 18-32
24. Schild G.C., Oxford J.S., and Virelizier J.L. Immunity to influenza. Dev Biol Stand 28 (1975) 253-272
25. Couch R.B., and Kasel J.A. Immunity to influenza in man. Annu Rev Microbiol 37 (1983) 529-549
26. Naikhin A.N., Artem'eva S.A., Ermachenko T.A., Vybornykh E.N., Kusticova IuG, Doroshenko E.V., et al. Antibody functional activity in immunization with influenza vaccines. Vopr Virusol 38 5 (1993) 204-207
27. Montgomery D.L., Shiver J.W., Leander K.R., Perry H.C., Friedman A., Martinez D., et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 12 9 (1993) 777-783
28. Zuercher A.W. Upper respiratory tract immunity. Viral Immunol 16 3 (2003) 279-289
29. Tomoda T., Morita H., Kurashige T., and Maassab H.F. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response. Vaccine 13 2 (1995) 185-190
30. Greenbaum E., Furst A., Kiderman A., Stewart B., Levy R., Schlasinger M., et al. Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine 20 7-8 (2002) 1232-1239